Can ageing be reversed? Landmark ER-100 therapy enters human testing

Life Biosciences has dosed the first participant in a Phase 1 trial of ER-100, a cellular-reprogramming treatment being studied for optic neuropathies, including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, or NAION.

Nature reported that the first person was treated in the landmark study on June 9, describing it as a trial aimed at coaxing aged cells in the eye into a younger state.

Also Read | 12 killed, 9 injured as gunmen open fire at informal settlement near Johannesburg, manhunt on

Where ageing meets its challenger

The Boston-based biotech said the study will primarily assess safety and tolerability, while also tracking visual function.

The company says that ER-100 is the first treatment from its epigenetic restoration platform, and it works by controlling the activity of three transcription factors—OCT4, SOX2, and KLF4—to help cells behave more like younger cells.

Co-founder David Sinclair, a Harvard genetics professor, called the dosing “an important moment for Life Bio and for the field of aging biology.”

Proceeding with due caution and a steady hand

The first injection was given into one eye of a single glaucoma patient, with the initial study expected to involve around 18 adults under close monitoring.

The trial is using a piloted approach because researchers remain cautious about the technique: cellular reprogramming is still experimental, and critics have pointed to safety concerns, including the possibility of abnormal cell growth.

As stem-cell biologist Paul Knoepfler put it, “A lot can go wrong.”

Also Read | Former Air Canada pilot charged after allegedly flying with forged credentials for 17 years

The longer game begins

Life Biosciences says ER-100 is the first cellular rejuvenation therapy using this technology to receive FDA clearance for human testing, and the company has said it is exploring wider applications beyond the eye, including age-related diseases such as fatty liver disease.

For now, the trial will determine whether the treatment can move from promising preclinical data to a safe human therapy with measurable effects on vision.

FAQs

Q1: What is ER-100 and how does it work?

Ans: ER-100 is an experimental gene therapy designed to make ageing cells behave more like younger cells through cellular reprogramming.

Q2: What conditions is the ER-100 human trial targeting?

Ans: The trial is testing ER-100 in patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION).